Bharat Biotech claims 77.8% efficacy of Covaxin in phase-3 trials

Announcing the much awaited safety and efficacy data from phase-3 clinical trials of Covaxin, the IMCR director Prof Balram Bhargava said Covaxin also worked well against all variant strains of SARS-CoV-2 including the Delta variant.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3hqHA9o
via IFTTT